Today's Trend
Axsome Therapeutics, Inc. (NASDAQ: AXSM) shares have been under pressure as investors weigh a strong recent run-up against signs the valuation may be getting stretched. Several commentary pieces published today questioned whether the stock is now fully priced after its one-year surge, which can weigh on momentum buying.
- HC Wainwright reiterated a Buy rating and $290 price target on Axsome Therapeutics, signaling continued upside potential despite recent estimate cuts.
- Axsome announced support for Mental Health Month and shared resources tied to its CNS-focused mission, reinforcing the company’s brand and patient advocacy position. Axsome Therapeutics Recognizes Mental Health Month
- Recent articles debated whether Axsome’s stock is starting to look fully valued after its sharp advance, suggesting the market may be reassessing how much growth is already priced in.
- Coverage also noted that the company’s story is evolving around Auvelity and AXS-05 developments, which could matter longer term but did not include a specific new catalyst in the headlines provided.
- HC Wainwright made a series of earnings estimate adjustments for fiscal 2026 and 2027, including cuts to several near- and medium-term quarters. While the firm kept a Buy rating, the revisions may have tempered enthusiasm around the speed of profitability.
- Analysts lowered near-term EPS estimates for Q2 2026, Q3 2026, Q1 2027, Q2 2027, Q3 2027, Q4 2027 and FY2026/FY2027, highlighting slower expected earnings progress than previously forecast.
- Other broker notes mentioned Hold coverage from Morgan Stanley, which may add to the view that upside is less certain after the stock’s rally.
Overall, AXSM appears to be pulling back as investors digest valuation concerns and analyst estimate revisions, even though Wall Street remains broadly constructive on the long-term pipeline.